Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile

Acta Paediatrica, International Journal of Paediatrics

Volumn 93, Issue 3, 2004, Pages 412-414

  Riedemann, S ^a,c   Reinhardt, G ^a   Ibarra, H ^a   Frosner G G ^b  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSITY OF MUNICH   (Germany)

^c NONE   (Chile)

Author keywords

Children; Epaxal ; Hepatitis A; Immunogenicity; Toddlers; Tolerability; Vaccine; Virosome

Indexed keywords

HEPATITIS A VACCINE; VIROSOME VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS A; HUMAN; IMMUNOGENICITY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILE; HEPATITIS A VACCINES; HUMANS; INFANT; REGRESSION ANALYSIS; VIROSOMES;

EID: 1542373572     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250410022774     Document Type: Article

References (17)

1. Tapia-Conyer R, Santos JI, Calvacanti AM, Uraneta E, Rivera L, Manterola A, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999; 61: 825-9
2. World Health Organization. Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec 2000; 5: 38-44
3. Tanaka J. Hepatitis A shift in epidemiology in Latin America. Vaccine 2000; 18: S57-60
4. Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 2000; 18: S65-7
5. Barzaga NG. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 2000; 18: S61-4
6. Bell BP. Hepatitis A vaccine. Pediatr Infect Dis J 2000; 19: 1187-8
7. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14: 38-58
8. Koff RS. Hepatitis A. Lancet 1998; 351: 1643-9
9. Ibarra H, Riedemann S, Siegel F, Toledo C, Reinhardt G. Acute hepatitis caused by virus A, E and non A-E in Chilean adults. Rev Med Chil 2002; 129: 523-30
10. Van Damme P. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine 2001; 19: 999-1002
11. Loutan L, Bovier P, Althaus B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343: 322-4
12. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-13
13. Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A: a randomized controlled trial. Vaccine 1996; 14: 982-6
14. Bovier PA, Althaus B, Glueck R, Chippaux A, Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 1999; 6: 228-33
15. Bovier P, Loutan L, Ambrosch F, Glück R, Herzog C. Clinical experience with an inactivated virosome formulated hepatitis A vaccine. Clin Microbiol Infect 2000; 6 Suppl 1: 249-50
16. Mayorga Pérez O, Herzog C, Zellmeyer M, Loáisiga A, Frösner G, Egger M. Efficacy of virosome hepatitis A vaccine in toddlers in Nicaragua: randomised placebo-controlled trial. J Infect Dis 2003; 188: 671-7
17. Bovier PA, Loutan L, Farinelli T, Bock J, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68: 489-93